Kainos Medicine Statistics
Total Valuation
Kainos Medicine has a market cap or net worth of KRW 35.56 billion. The enterprise value is 37.38 billion.
| Market Cap | 35.56B |
| Enterprise Value | 37.38B |
Important Dates
The last earnings date was Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kainos Medicine has 32.71 million shares outstanding. The number of shares has increased by 8.89% in one year.
| Current Share Class | 32.71M |
| Shares Outstanding | 32.71M |
| Shares Change (YoY) | +8.89% |
| Shares Change (QoQ) | -8.05% |
| Owned by Insiders (%) | 22.73% |
| Owned by Institutions (%) | n/a |
| Float | 22.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 37.87 |
| PB Ratio | 4.54 |
| P/TBV Ratio | 20.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.68 |
| EV / Sales | 39.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.85 |
Financial Position
The company has a current ratio of 3.00, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.00 |
| Quick Ratio | 2.43 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | -243.10 |
Financial Efficiency
Return on equity (ROE) is -95.23% and return on invested capital (ROIC) is -50.64%.
| Return on Equity (ROE) | -95.23% |
| Return on Assets (ROA) | -46.11% |
| Return on Invested Capital (ROIC) | -50.64% |
| Return on Capital Employed (ROCE) | -113.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kainos Medicine has paid 1.14 million in taxes.
| Income Tax | 1.14M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.03% in the last 52 weeks. The beta is 1.27, so Kainos Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 1.27 |
| 52-Week Price Change | -73.03% |
| 50-Day Moving Average | 1,104.96 |
| 200-Day Moving Average | 1,939.78 |
| Relative Strength Index (RSI) | 50.94 |
| Average Volume (20 Days) | 481,084 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kainos Medicine had revenue of KRW 938.87 million and -10.15 billion in losses. Loss per share was -334.62.
| Revenue | 938.87M |
| Gross Profit | 657.00M |
| Operating Income | -8.94B |
| Pretax Income | -10.15B |
| Net Income | -10.15B |
| EBITDA | -8.19B |
| EBIT | -8.94B |
| Loss Per Share | -334.62 |
Balance Sheet
The company has 4.22 billion in cash and 225.96 million in debt, giving a net cash position of 4.00 billion or 122.15 per share.
| Cash & Cash Equivalents | 4.22B |
| Total Debt | 225.96M |
| Net Cash | 4.00B |
| Net Cash Per Share | 122.15 |
| Equity (Book Value) | 7.83B |
| Book Value Per Share | 69.55 |
| Working Capital | 3.76B |
Cash Flow
In the last 12 months, operating cash flow was -6.38 billion and capital expenditures -5.52 million, giving a free cash flow of -6.39 billion.
| Operating Cash Flow | -6.38B |
| Capital Expenditures | -5.52M |
| Free Cash Flow | -6.39B |
| FCF Per Share | -195.21 |
Margins
| Gross Margin | 69.98% |
| Operating Margin | -952.20% |
| Pretax Margin | -1,080.64% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kainos Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.89% |
| Shareholder Yield | -8.89% |
| Earnings Yield | -28.54% |
| FCF Yield | -17.96% |
Stock Splits
The last stock split was on June 24, 2022. It was a reverse split with a ratio of 0.2.
| Last Split Date | Jun 24, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Kainos Medicine has an Altman Z-Score of -2.79 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.79 |
| Piotroski F-Score | 2 |